P38mapk inhibitor sb202190

The incubation medium RPMI 1640, FBS, penicillin/streptomycin and Ficoll were obtained from Wisent (St-Bruno, QC, Canada). Dextran was from Sigma-Aldrich Corp. (St. Louis, MO, USA). Recombinant human IL-32γ, ApoStat detection kit and TACS annexin V-FITC apoptosis detection kit were purchased from R&D Systems (Minneapolis, MN, USA). The inhibitors of PI3K/Akt (LY294002) and MEK-1 (U0126) were obtained from Cayman Chemical (Ann Arbor, Michigan, USA). The JNK inhibitor (SP600125) was from Calbiochem (San Diego, CA, USA), p38 MAPK inhibitor (SB202190) was obtained from Invivogen (San Diego, CA, USA), and MAPK inhibitor negative control (SB202474) was from Life Technologies (Carlsbad, CA, USA). The fluorescein active caspase-3 staining kit was purchased from BioVision (Milpitas, CA, USA) and the caspase-3 (active form) apoptosis kit was from BD Biosciences (San Jose, CA, USA). Antibodies were from different sources as follows: anti-human CD66b-FITC and control isotype were from BioLegend (San Diego, CA, USA), anti-human MCL-1 and anti-human PCNA (PC-10) were from Santa Cruz Biotechnologies (Dallas, TX, USA), anti-human phopho-p38 and anti-human p38 MAPK were from Cell Signaling Technologies (Danvers, MA, USA), and anti-human β-actin was from Sigma-Aldrich Corp. (St. Louis, MO, USA).